{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:35:44Z","timestamp":1791844544261,"version":"4.3.4"},"reference-count":131,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Plaque radiotherapy is an effective treatment modality for medium-sized ocular tumors such as uveal melanoma. The authors review the available literature and concisely summarize the current state of the art of ophthalmic plaque brachytherapy. The choice of radioisotope, which includes Ruthenium-106 and Iodine-125, depends on the intended treatment duration, tumor characteristics, and side effect profiles. Ophthalmic plaques may be customized to allow for the delivery of a precise radiation dose by adjusting seed placement and plaque shape to minimize collateral tissue radiation. High dose rate (HDR) brachytherapy, using beta (e.g., Yttrium-90) and photon-emitting sources (e.g., Ytterbium-169, Selenium-75), allows for rapid radiation dose delivery, which typically lasts minutes, compared to multiple days with low-dose plaque brachytherapy. The efficacy of Ruthenium-106 brachytherapy for uveal melanoma varies widely, with reported local control rates between 59.0% and 98.0%. Factors influencing outcomes include tumor size, thickness, anatomical location, and radiation dose at the tumor apex, with larger and thicker tumors potentially exhibiting poorer response and a higher rate of complications. Plaque brachytherapy is effective for selected tumors, particularly uveal melanoma, providing comparable survival rates to enucleation for medium-sized tumors. The complications of plaque brachytherapy are well described, and many of these are treatable.<\/jats:p>","DOI":"10.3390\/cancers16193386","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:45:52Z","timestamp":1727937952000},"page":"3386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Plaque Radiotherapy for Ocular Melanoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-4707","authenticated-orcid":false,"given":"George Naveen","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, National University Health System, Singapore 119228, Singapore"},{"name":"Department of Ophthalmology, National University of Singapore, Singapore 119222, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2539-3865","authenticated-orcid":false,"given":"I-Ling","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Health System, Singapore 119228, Singapore"},{"name":"Department of Ophthalmology, National University of Singapore, Singapore 119222, Singapore"},{"name":"School of Medicine, China Medical University, Taichung 404, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingam","family":"Gopal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National University Health System, Singapore 119228, Singapore"},{"name":"Department of Ophthalmology, National University of Singapore, Singapore 119222, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bjo.14.4.145","article-title":"Choroidal sarcoma treated by the intraocular insertion of radon seeds","volume":"14","author":"Moore","year":"1930","journal-title":"Br. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bjo.50.3.147","article-title":"Radiotherapy for malignant melanoma of the choroid","volume":"50","author":"Stallard","year":"1966","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00000421-198704000-00050","article-title":"Results after beta-irradiation (106Ru\/106Rh) of choroidal melanomas. Twenty years\u2019 experience","volume":"10","author":"Lommatzsch","year":"1987","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0161-6420(80)35194-4","article-title":"Radiotherapy of choroidal melanoma with iodine-125","volume":"87","author":"Packer","year":"1980","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1259\/0007-1285-49-582-551","article-title":"The treatment of ophthalmic tumours with low-energy sources","volume":"49","author":"Sealy","year":"1976","journal-title":"Br. J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2008.12.027","article-title":"Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients","volume":"116","author":"Finger","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.brachy.2008.05.002","article-title":"The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs","volume":"7","author":"Rivard","year":"2008","journal-title":"Brachytherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0039-6257(97)00088-X","article-title":"Radiation therapy for choroidal melanoma","volume":"42","author":"Finger","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"ref_9","first-page":"73","article-title":"Results of beta-therapy of choroidal melanoma","volume":"25","author":"Vakulenko","year":"1980","journal-title":"Med. Radiol."},{"key":"ref_10","first-page":"14","article-title":"Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and their prevention","volume":"113","author":"Brovkina","year":"1997","journal-title":"Vestn. Oftalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2011.11.002","article-title":"106Ruthenium plaque therapy (RPT) for retinoblastoma","volume":"84","author":"Murakami","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","unstructured":"Collaborative Ocular Melanoma Study Group (1995). Chapter 12: Radiation therapy, COMS Manual of Procedures."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2006). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch. Ophthalmol., 124, 1684\u20131693.","DOI":"10.1001\/archopht.124.12.1684"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1758834018757175","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: Where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"American Brachytherapy Society\u2014Ophthalmic Oncology Task Force (2014). The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy, 13, 1\u201314.","DOI":"10.1016\/j.brachy.2014.02.230"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ajo.2003.12.032","article-title":"Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years\u2019 experience with beta-rays)","volume":"137","author":"Rouberol","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5114\/jcb.2021.103586","article-title":"Plaque brachytherapy in iris and iridociliary melanoma: A systematic review of efficacy and complications","volume":"13","author":"Karimi","year":"2021","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33594\/000000505","article-title":"Interventional radio-therapy (brachytherapy) in eyelid and ocular surface tumors: A review for treatment of na\u00efve and recurrent malignancies","volume":"30","author":"Pagliara","year":"2022","journal-title":"Neurosignals"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.prro.2019.05.007","article-title":"The role of eye plaque brachytherapy and MR imaging in the management of diffuse choroidal hemangioma: An illustrative case report and literature review","volume":"9","author":"Lewis","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41433-020-0879-z","article-title":"Management of conjunctival melanoma with local excision and adjuvant brachytherapy","volume":"35","author":"Brouwer","year":"2021","journal-title":"Eye"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0360-3016(90)90077-W","article-title":"An interactive treatment planning system for ophthalmic plaque radiotherapy","volume":"18","author":"Astrahan","year":"1990","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/107327480401100504","article-title":"The Collaborative Ocular Melanoma Study: An Overview","volume":"11","author":"Margo","year":"2004","journal-title":"Cancer Control"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2001). Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. visual acuity after 3 years COMS report no. 16. Ophthalmology, 108, 348\u2013366.","DOI":"10.1016\/S0161-6420(00)00526-1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5114\/jcb.2023.132658","article-title":"A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma","volume":"15","author":"Miguel","year":"2023","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4149\/neo_2018_171209N808","article-title":"Uveal melanoma survival rates after single dose stereotactic radiosurgery","volume":"65","author":"Furdova","year":"2018","journal-title":"Neoplasma"},{"key":"ref_30","first-page":"377","article-title":"No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma","volume":"57","author":"Furdova","year":"2010","journal-title":"Neoplasma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5114\/jcb.2018.77849","article-title":"Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after episcleral brachytherapy. A 20-year retrospective analysis from a single institution: Part I","volume":"10","author":"Miguel","year":"2018","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brachy.2015.12.001","article-title":"Brachytherapy vs. external beam radiotherapy for choroidal melanoma: Sur-vival and patterns-of-care analyses","volume":"15","author":"Abrams","year":"2016","journal-title":"Brachytherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s11864-024-01212-5","article-title":"External Beam Radiotherapy in the Management of Uveal Melanoma","volume":"25","author":"Yilmaz","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1002\/mp.13996","article-title":"AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of Task Group 221","volume":"47","author":"Thomson","year":"2020","journal-title":"Med. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brachy.2011.01.006","article-title":"A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using 125I, 103Pd, and 131Cs and historical perspective","volume":"10","author":"Leonard","year":"2011","journal-title":"Brachytherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/S0004-27492004000300015","article-title":"Single institutional retrospective analysis: Treatment of choroidal melanomas with cobalt-60 brachytherapy","volume":"67","author":"Pellizzon","year":"2004","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0002-9394(14)70584-7","article-title":"Cobalt-60 treatment of choroidal hemangiomas","volume":"121","author":"Zografos","year":"1996","journal-title":"Am. J. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0360-3016(91)90679-X","article-title":"Cobalt-60 plaques in recurrent retinoblastoma","volume":"21","author":"Fass","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5114\/jcb.2014.55003","article-title":"Superficial ocular malignancies treated with strontium-90 brachytherapy: Long-term outcomes","volume":"7","author":"Laskar","year":"2015","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bjo.2005.068460","article-title":"18 years\u2019 experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma","volume":"89","author":"Spileers","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0360-3016(98)00431-3","article-title":"Postoperative irradiation of pterygium with 90Sr eye applicator","volume":"43","author":"Fukushima","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s004170050059","article-title":"Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy: A retrospective study of 46 patients treated between 1983 and 1995","volume":"236","author":"Missotten","year":"1998","journal-title":"Graefe\u2019s Arch Clin. Exp. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dupere, J.M., Munro, J.J., and Medich, D.C. (2021). Shielded high dose rate ocular brachytherapy using Yb-169. Phys. Med. Biol., 66.","DOI":"10.1088\/1361-6560\/ac02d6"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0360-3016(94)90314-X","article-title":"Episcleral iridium-192 wire therapy for choroidal melanomas","volume":"30","author":"Valverde","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/ICU.0000000000000468","article-title":"Plaque brachytherapy for posterior uveal melanoma in 2018: Improved techniques and expanded indications","volume":"29","author":"Reichstein","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_46","unstructured":"National Nuclear Data Center (2024, March 16). Chart of Nuclides, Available online: http:\/\/www.nndc.bnl.gov\/chart\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/OPTH.S235265","article-title":"Comparison of iodide-125 and ruthenium-106 brachytherapy in the treatment of choroidal melanomas","volume":"14","author":"Ghassemi","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/bjophthalmol-2018-313419","article-title":"Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of \u22655.5 mm","volume":"104","author":"Trocme","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/j.prro.2013.08.004","article-title":"Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma","volume":"4","author":"Takiar","year":"2014","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/CMR.0000000000000420","article-title":"Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma","volume":"28","author":"Danish","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.oret.2020.01.010","article-title":"Anti\u2013VEGF therapy immediately after plaque radiation therapy prevents or delays radiation maculopathy","volume":"4","author":"Powell","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1177\/1120672120914235","article-title":"Palladium-103 plaque therapy for multifocal iris melanoma: Radiation of the entire anterior segment of the eye","volume":"31","author":"Finger","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101636","DOI":"10.1016\/j.ajoc.2022.101636","article-title":"Palladium-103 plaque brachytherapy for retinoblastoma: Long-term follow up","volume":"27","author":"Maheshwari","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1118\/1.4749933","article-title":"Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS","volume":"39","author":"Astrahan","year":"2012","journal-title":"Med. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1118\/1.597164","article-title":"Dosimetry for 125I seed (model 6711) in eye plaques","volume":"20","author":"Anderson","year":"1993","journal-title":"Med. Phys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1118\/1.3002412","article-title":"Monte Carlo dosimetry for an eye plaque brachytherapy","volume":"35","author":"Thomson","year":"2008","journal-title":"Med. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00417-017-3703-0","article-title":"Juxtapapillary and circumpapillary choroidal melanoma: Globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy","volume":"255","author":"Hegde","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"021717","DOI":"10.1118\/1.4861715","article-title":"Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom","volume":"41","author":"Lesperance","year":"2014","journal-title":"Med. Phys."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"031706","DOI":"10.1118\/1.4864474","article-title":"Monte Carlo dosimetry for 103Pd,125I, and131Cs ocular brachytherapy with various plaque models using an eye phantom","volume":"41","author":"Lesperance","year":"2014","journal-title":"Med. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.brachy.2020.01.001","article-title":"Influence of tumor shape and location in eye plaque brachytherapy dosimetry","volume":"19","author":"Studenski","year":"2020","journal-title":"Brachytherapy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0167-8140(00)00334-0","article-title":"The treatment of choroidal melanoma with 198Au plaque brachytherapy","volume":"59","author":"Karvat","year":"2001","journal-title":"Radiother. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0167-8140(04)80233-0","article-title":"Dosimetric study of the 15 mm ropes eye plaque","volume":"71","author":"Ballester","year":"2004","journal-title":"Radiother. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1118\/1.1993828","article-title":"Design and dosimetric considerations of a modified COMS plaque: The reusable \u201cseed-guide\u201d insert","volume":"32","author":"Astrahan","year":"2005","journal-title":"Med. Phys."},{"key":"ref_64","unstructured":"EyePhysics (2024, April 05). Plaque Simulator. Available online: https:\/\/www.eyephysics.com\/PS\/Index.html."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ophtha.2011.11.011","article-title":"Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/bjophthalmol-2016-309153","article-title":"Episcleral brachytherapy of uveal melanoma: Role of intraoperative echographic confirmation","volume":"101","author":"Aziz","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Schefler, A.C., and Yu, H.J. (2021). Surgical considerations of radiation plaques and enucleation. Uveal Melanoma: Biology and Management, Springer International Publishing.","DOI":"10.1007\/978-3-030-78117-0_7"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/24741264241227684","article-title":"Yttrium-90 episcleral plaque brachytherapy for choroidal melanoma","volume":"8","author":"Finger","year":"2024","journal-title":"J. Vitreoretinal Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jrr\/rrt027","article-title":"The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer","volume":"54","author":"Yoshioka","year":"2013","journal-title":"J. Radiat. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.brachy.2023.02.004","article-title":"First clinical implementation of yttrium-90 disc brachytherapy after FDA clearance","volume":"22","author":"Finger","year":"2023","journal-title":"Brachytherapy"},{"key":"ref_71","first-page":"e172","article-title":"Dosimetry of beta-emitting brachytherapy sources for age-related macular degeneration","volume":"45","author":"Rivard","year":"2018","journal-title":"Med. Phys."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Semeniuk, O., Yu, E., and Rivard, M.J. (2024). Current and emerging radiotherapy options for uveal melanoma. Cancers, 16.","DOI":"10.3390\/cancers16051074"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.eye.6700306","article-title":"Beta irradiation: New uses for an old treatment: A review","volume":"17","author":"Kirwan","year":"2003","journal-title":"Eye"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18","volume":"119","author":"Earle","year":"2001","journal-title":"Arch Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Toro, M.D., Gozzo, L., Tracia, L., Cicci\u00f9, M., Drago, F., Bucolo, C., Avitabile, T., Rejdak, R., Nowomiejska, K., and Zweifel, S. (2021). New therapeutic perspectives in the treatment of uveal melanoma: A systematic review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101311"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-01947-1","article-title":"The immune cell landscape of metastatic uveal melanoma correlates with overall survival","volume":"40","author":"Tosi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Tanaka, R., Terai, M., Londin, E., and Sato, T. (2021). The role of HGF\/MET signaling in metastatic uveal melanoma. Cancers, 13.","DOI":"10.3390\/cancers13215457"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0b013e32835b7154","article-title":"Elevated blood \u03b2-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma","volume":"23","author":"Triozzi","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00018-020-03612-w","article-title":"Emerging roles of microRNAs and their implications in uveal melanoma","volume":"78","author":"Yang","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ophtha.2007.06.012","article-title":"Cytogenetics of uveal melanoma: A 7-year clinical experience","volume":"114","author":"Damato","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_83","unstructured":"DeVita, V.T., Lawrence, T.S., and Rosenberg, S.A. (2014). Intraocular melanoma. Cancer: Principles and Practice of Oncology, Lippincott, Williams & Wilkins. [10th ed.]."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/15384047.2015.1046021","article-title":"miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications","volume":"16","author":"Ragusa","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","article-title":"Treatment of metastatic uveal melanoma with intravenous fotemustine","volume":"23","author":"Spagnolo","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma","volume":"21","author":"Diallo","year":"2016","journal-title":"Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid\u2013paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CMR.0b013e328311aaa1","article-title":"A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma","volume":"18","author":"Bedikian","year":"2008","journal-title":"Melanoma Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdl009","article-title":"Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients","volume":"17","author":"Peters","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejrad.2009.03.064","article-title":"Transarterial chemoembolization of liver metastases in patients with uveal melanoma","volume":"74","author":"Huppert","year":"2010","journal-title":"Eur. J. Radiol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Bethlehem, M.S., Katsarelias, D., and Olofsson Bagge, R. (2021). Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases. Cancers, 13.","DOI":"10.3390\/cancers13184726"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cncr.10996","article-title":"Chemo-immunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma","volume":"95","author":"Muhonen","year":"2002","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0606-5","article-title":"Immunotherapy for the treatment of uveal melanoma: Current status and emerging therapies","volume":"19","author":"Komatsubara","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ctrv.2007.12.002","article-title":"Targeted therapy for uveal melanoma","volume":"34","author":"Triozzi","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bjo.80.8.732","article-title":"Radiation-related complications after ruthenium plaque radiotherapy of uveal melanoma","volume":"80","author":"Summanen","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000071345","article-title":"Tumour regression of uveal melanoma after ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator","volume":"217","author":"Georgopoulos","year":"2003","journal-title":"Ophthalmologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2005.02.017","article-title":"Local tumor control after 106Ru brachytherapy of choroidal melanoma","volume":"63","author":"Damato","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5114\/jcb.2021.106191","article-title":"Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: A systematic review and meta-analysis","volume":"13","author":"Karimi","year":"2021","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(02)01181-8","article-title":"Plaque radiotherapy for large posterior uveal melanomas (\u22658-mm thick) in 354 consecutive patients","volume":"109","author":"Shields","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0002-9394(98)00445-0","article-title":"Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement","volume":"127","author":"Shields","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.brachy.2014.04.002","article-title":"(106)Ru plaque brachytherapy for uveal melanoma: Factors associated with local tumor recurrence","volume":"13","author":"Barker","year":"2014","journal-title":"Brachytherapy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jcp.2005.033613","article-title":"Malignant melanoma of the ciliary body presenting as extraocular metastasis in the temporalis muscle","volume":"60","author":"Oittinen","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0161-6420(01)00797-7","article-title":"Plaque radiotherapy for retinoblastoma: Long-term tumor control and treatment complications in 208 tumors","volume":"108","author":"Shields","year":"2001","journal-title":"Ophthalmology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2356::AID-CNCR26>3.0.CO;2-V","article-title":"125I plaque therapy for uveal melanoma: Analysis of the impact of time and dose factors on local control","volume":"77","author":"Quivey","year":"1996","journal-title":"Cancer"},{"key":"ref_107","first-page":"939","article-title":"Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients","volume":"158","author":"Bol","year":"2014","journal-title":"Arch. Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s004170100301","article-title":"Alterations in expression of mucin, tenascin-C, and syndecan-1 in the conjunctiva following retinal surgery and plaque radiotherapy","volume":"239","author":"Heimann","year":"2001","journal-title":"Graefes Arch Clin. Exp. Ophthalmol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/jcb.2019.87407","article-title":"Complications and adverse events of plaque brachytherapy for ocular melanoma","volume":"11","author":"Peddada","year":"2019","journal-title":"J. Contemp. Brachyther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjo.84.9.1068","article-title":"Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy","volume":"84","author":"Finger","year":"2000","journal-title":"Br. J. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1442-9071.2005.01067.x","article-title":"New Zealand experience of I-125 brachytherapy for choroidal melanoma","volume":"33","author":"Stack","year":"2005","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0360-3016(93)90277-3","article-title":"High intensity 125-iodine (125I) plaque treatment of uveal melanoma","volume":"26","author":"Quivey","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ophtha.2004.09.028","article-title":"Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma","volume":"112","author":"Detorakis","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archopht.1963.00960050788011","article-title":"Sympathetic Ophthalmia Associated with Malignant Melanoma","volume":"70","author":"Easom","year":"1963","journal-title":"Arch Ophthalmol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/eye.2009.43","article-title":"Ocular complications following I-125 brachytherapy for choroidal melanoma","volume":"23","author":"Wen","year":"2009","journal-title":"Eye"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IJG.0000000000001393","article-title":"Glaucoma after iodine-125 brachytherapy for uveal melanoma: Incidence and risk factors","volume":"29","author":"Kim","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2007). Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine-125 brachytherapy in the Collaborative Ocular Melanoma Study. COMS Report No. 27. Ophthalmology, 114, 1363\u20131371.","DOI":"10.1016\/j.ophtha.2006.10.039"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0360-3016(93)90278-4","article-title":"Treatment of choroidal melanoma with I-125 plaque","volume":"26","author":"Fontanesi","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/eye.1991.39","article-title":"Radiation retinopathy: Clinical, histopathological, ultrastructural, and experimental correlations","volume":"5","author":"Archer","year":"1991","journal-title":"Eye"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/bjo.2004.052159","article-title":"Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy","volume":"89","author":"Finger","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","article-title":"Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.ophtha.2004.03.027","article-title":"Ocular complications after iodine brachytherapy for large uveal melanomas","volume":"111","author":"Puusaari","year":"2004","journal-title":"Ophthalmology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00006982-200605000-00007","article-title":"Intravitreal triamcinolone acetonide for acute radiation papillopathy","volume":"26","author":"Shields","year":"2006","journal-title":"Retina"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.47102\/annals-acadmedsg.V35N3p151","article-title":"Hyperbaric oxygen therapy for radiation-induced optic neuropathy","volume":"35","author":"Levy","year":"2006","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.eye.6701361","article-title":"125I plaque brachytherapy for anterior uveal melanomas","volume":"18","author":"Levy","year":"2004","journal-title":"Eye"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0161-6420(02)01273-3","article-title":"Iodine-125 plaque brachytherapy vs transscleral tumor resection in the treatment of large uveal melanomas","volume":"109","author":"Bechrakis","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.169.1.3420267","article-title":"Choroidal melanoma: I-125 plaque therapy","volume":"169","author":"Bosworth","year":"1988","journal-title":"Radiology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/archopht.1987.01060100096035","article-title":"Choroidal melanoma treatment with iodine-125 brachytherapy","volume":"105","author":"Garretson","year":"1987","journal-title":"Arch Ophthalmol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0360-3016(01)02723-7","article-title":"Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: Dose and dose rate effects","volume":"52","author":"Jones","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaapos.2003.09.007","article-title":"Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma","volume":"8","author":"Sener","year":"2004","journal-title":"J. AAPOS"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaapos.2007.04.005","article-title":"Strabismus in adults with uveal melanoma following episcleral plaque brachytherapy","volume":"11","author":"Dawson","year":"2007","journal-title":"J. AAPOS"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:55Z","timestamp":1760112595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":131,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16193386"],"URL":"https:\/\/doi.org\/10.3390\/cancers16193386","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}